E-Mail
The Worldwide Innovative Network in personalized cancer medicine consortium - WIN Consortium announces the publication of the Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival for cancer patients in
NPJ Precision Oncology (10.1038/s41698-021-00171-6)
Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient s tumor for all markers related to all possible targeted therapies becomes infeasible due to limited amount of tissue usually obtained by biopsies. In addition, the current companion diagnostic approach used for most targeted therapies provides limited treatment options, with a binary yes/no expected response to a drug and no recommendation for which treatment, among a range of possible options, is likely to be the best option